Related Experiment Video
Updated: Apr 16, 2026
Flexible Organic Electronic Devices for Pulsed Electric Field Therapy of Glioblastoma
Published on: August 9, 2022
Should patients with asymptomatic pompe disease be treated? A nationwide study in France
Andoni Echaniz-Laguna1, Robert-Yves Carlier2, Kenza Laloui3
1Centre de Référence des Maladies Neuromusculaires, Département de Neurologie, Hôpital de Hautepierre 1, Avenue Molière, 67098, Strasbourg, France.
Introduction:
Acid α-glucosidase deficiency, that is, Pompe disease, is a glycogenosis for which enzyme replacement therapy (ERT) is available. It is not known whether patients diagnosed at an asymptomatic stage should be treated to prevent progression of the disease.
Methods:
We investigated 7 patients with asymptomatic Pompe disease identified from the French Pompe registry.
Results:
The patients had a mean age of 45 (range 24-75) years, a median follow-up duration of 2 (range 1-22) years, and normal clinical examination, pulmonary function tests (PFTs), and echocardiography. All presented with at least 1 subclinical abnormality, including hyperCKemia, vacuolar myopathy, and muscle MRI abnormalities, suggesting that subclinical myopathy was present in all cases.
Conclusions:
Asymptomatic Pompe disease may remain clinically silent for decades, and affected patients should be monitored closely for overt myopathy using clinical examination, PFTs, and muscle MRI to determine when to start ERT.
More Related Videos
07:37Click-Chemistry Based Fluorometric Assay for Apolipoprotein N-acyltransferase from Enzyme Characterization to High-Throughput Screening
Published on: May 13, 2020
15:04Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
Published on: January 19, 2019